Insulin aspart Sanofi is a medicine used to control blood glucose (sugar) levels in patients from one year of age who have diabetes. Insulin aspart Sanofi is a ‘biosimilar medicine’. This means that Insulin aspart Sanofi is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Insulin aspart Sanofi is NovoRapid. Insulin aspart Sanofi contains the active substance insulin aspart, a rapid-acting insulin.
Therapeutic Indication
### Therapeutic indication Insulin aspart Sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
Therapeutic Area (MeSH)
ATC Code
A10AB05
ATC Item
insulin aspart
Pharmacotherapeutic Group
Drugs used in diabetes
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| insulin aspart | N/A | 门冬胰岛素 |
EMA Name
Insulin aspart Sanofi
Medicine Name
Insulin aspart Sanofi
Aliases
N/ANo risk management plan link.
